12 Results for "

mouse VEGFA

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "mouse VEGFA" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P990148

Target:  

VEGFR

Research Areas:  

Cancer

Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived IgG2a κ type antibody inhibitor, tragrting to mouse VEGF-A with high affinity. Anti-Mouse VEGF-A Antibody (2G11-2A05) shows good anti-tumor effect in gastric cancer xenograft models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P72775
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: VEGF-AA; Vascular endothelial growth factor A; VPF; VEGFA
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P99116
CAS No.: 1607793-29-2
Synonyms: RG7716; RO-6867461
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
loading...
    loading...
Cat. No.: HY-RS16537
Research Areas:  

Others

Vegfa Mouse Pre-designed siRNA Set A contains three designed siRNAs for Vegfa gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P990082
CAS No.: 1610010-57-5
Synonyms: APX-003; BD-0801

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease Cancer

Suvemcitug (APX-003) is a selective humanized rabbit monoclonal IgG1 (κ) anti-VEGF antibody. Suvemcitug inhibits the binding of VEGF to purified VEGFR1 (IC50 = 21.0 ng/mL) and VEGFR2 (IC50 = 275.4 ng/mL). Suvemcitug suppresses tumor angiogenesis, tumor growth and metastasis. Suvemcitug is applicable to research related to epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer .
loading...
    loading...
Cat. No.: HY-163760
CAS No.: 2667585-44-4
Target:  

HuR MMP

Research Areas:  

Cancer

ZM-32 is an inhibitor for human antigen R (HuR), that downregulates the expression of VEGF-A and MMP9, and thus inhibits breast cancer tumor angiogenesis. ZM-32 exhibits broad-spectrum anti-proliferative effects in a variety of cancer cell lines, and exhibits antitumor efficacy against MDA-MB-231 in mouse models .
loading...
    loading...
Cat. No.: HY-P70761
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGFA; VEGFA164; VEGF164
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-182700
CAS No.: 717863-53-1
Target:  

Complement System VEGFR

Research Areas:  

Cancer

NRPa-308 is a potent and orally active Neuropilin-1 (NRP-1) antagonist with an IC50 of 42 μM for inhibiting VEGF-A165 binding to NRP-1. NRPa-308 blocks the specific interaction between VEGF-A165 and NRP-1. NRPa-308 effectively suppresses angiogenesis in vitro and in vivo and reduces the viability of a broad spectrum of human solid and haematological cancer cells. NRPa-308 inhibits tumor growth and prolongs median survival in a human breast cancer xenograft mouse model. NRPa-308 can be used for the research of multiple human malignancies including solid tumors and hematological cancers .
loading...
    loading...
Cat. No.: HY-P992518

Target:  

VEGFR PD-1/PD-L1

Research Areas:  

Cancer

Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .
loading...
    loading...
Cat. No.: HY-P78686
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P78812
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P78814
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF
Species:  
Source:  
loading...
    loading...
  • 1